Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ocular Therapeutix ( (OCUL) ) just unveiled an announcement.
On September 30, 2025, Ocular Therapeutix announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at $12.53 per share, aiming to raise approximately $475 million. The net proceeds are expected to fund clinical trials, manufacturing scale-up, and pre-commercialization activities for AXPAXLI, as well as general corporate purposes. The offering is anticipated to close on October 1, 2025, and is expected to extend the company’s cash runway into 2028, supporting its strategic initiatives and operational growth.
The most recent analyst rating on (OCUL) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Ocular Therapeutix stock, see the OCUL Stock Forecast page.
Spark’s Take on OCUL Stock
According to Spark, TipRanks’ AI Analyst, OCUL is a Neutral.
Ocular Therapeutix’s stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. However, the technical analysis shows positive momentum, which is a favorable factor. The earnings call provided optimism with strategic advancements and a strong cash position, but the valuation remains unattractive due to negative profitability metrics. Overall, the stock presents a mixed outlook with significant financial risks but potential upside from clinical advancements.
To see Spark’s full report on OCUL stock, click here.
More about Ocular Therapeutix
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience. It develops products such as AXPAXLI, an investigational axitinib intravitreal hydrogel for retinal diseases, currently in Phase 3 trials for wet age-related macular degeneration and planned for non-proliferative diabetic retinopathy. The company also markets DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain post-surgery, and is developing OTX-TIC for glaucoma.
Average Trading Volume: 2,214,348
Technical Sentiment Signal: Buy
Current Market Cap: $2.18B
For detailed information about OCUL stock, go to TipRanks’ Stock Analysis page.